Dr Carolyn Staton [PhD, MBiochem, SFHEA]
Department of Oncology & Metabolism
The Medical School
Beech Hill Road
Tel: +44 (0) 114 215 9063
I first joined the University of Sheffield in 1997 to undertake my PhD studies into the role of fibrinogen and its related fragments on the process of tumour angiogenesis. During the course of my PhD I discovered a number of novel anti-angiogenic agents which were patented by the University of Sheffield and led to the funding of my postdoctoral research position to investigate these further. These studies led to me being given the AACR – Novartis Scholar In Training Award (2000) and the BACR Translational Research Award (2005) - both in open competition.
In 2004 I was appointed to a lectureship within the Microcirculation Research Group in the Academic Unit of Surgical Oncology and I am now a senior lecturer.
My research is focused on the regulation of angiogenesis, the development of new blood vessels from the pre-existing vasculature, in wound healing and tumour development and progression.
Angiogenesis and haemostasis, the coagulation cascade leading to clot formation, are among the most consistent host responses associated with cancer. Many haemostatic proteins stimulate angiogenesis by up-regulating the expression of vascular endothelial growth factor (VEGF) and its receptors on endothelial cells.
Other haemostatic proteins act directly on endothelial cells to inhibit or stimulate angiogenesis. Moreover, recently proteins originally identified as important in neuronal guidance are now suspected to be involved in regulating angiogenesis, both positively and negatively. Thus a comprehensive understanding of the relationships between these important processes under normal conditions (such as wound healing) and in the manner in which this changes during development and progression of cancer has implications for cancer therapy.
Collaborative research with colleagues in Sheffield also includes investigating the effects of HDACi on the expression of these and other angiogenesis related proteins in cancer, the potential anti-cancer effects of metformin and the potential education of tumour promoting macrophages by the tumour vasculature.
Currently my major teaching interest is in leading, developing and teaching on the MSc(Res) in Translational Oncology. This is an intense one year masters course featuring five months of taught modules giving students a thorough grounding in all aspects of translational oncology before moving on to the six months research project. As well as course lead, I am the module leader for the Tumour Microenvironment and the Research Project modules.
I am also involved as module lead for the Molecular Pathology of Cancer module in the MSc Genomic Medicine course, and teach on the MSc in Molecular Medicine and the MSc in Human Nutrition courses, as well as teaching undergraduates on the MBChB course. More recently I have become involved in undergraduate teaching in MBB on their Molecular biology and Biochemical Basis of Human disease modules.
• Senior Fellow of the Higher Education Academy
• Honorary Treasurer of the British Microcirculation Society
• Peer Review of grant applications for funding bodies including MRC, Wellcome Trust and Breast Cancer Now.
• I am on the editorial board of the International Journal of Experimental Pathology and the review editorial board of Frontiers in Vascular Physiology
• Ethics reviewer for the School of Medicine
• University of Sheffield and School of Medicine Athena SWAN self-assessment team member.
• Role of class 3 semaphorins in cancer progression
• Anti-breast cancer effects of metformin
• Down regulation of angiogenic pathways by HDAC inhibition
• HDAC inhibitors with radiotherapy as a novel combination for the treatment of breast cancer
• Education of tumour promoting macrophages by the tumour vasculature
• Regulation of angiogenesis and vascular regression in human dermal wound healing
For a full list of publications please visit myPublications